Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to cut COPD attacks in half

NCT ID NCT07330310

Not yet recruiting Disease control Sponsor: Joincare Pharmaceutical Group Industry Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests an experimental injection called JKN2401 in 888 people with moderate-to-severe COPD. The goal is to see if it can safely reduce the number of serious flare-ups compared to a placebo. Participants will receive injections every four weeks and be monitored for about a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JKN2401 injection
What this could lead to
If successful, JKN2401 could become a new treatment option to reduce the number of serious COPD flare-ups, helping patients breathe easier and stay out of the hospital.
What could go wrong
This is a large Phase 3 trial, but it's still experimental. The drug may not work better than placebo, and side effects are possible. Results will take time to analyze.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.